Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by equities research analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.
Several other research firms have also weighed in on KPTI. HC Wainwright lowered Karyopharm Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, July 16th. Robert W. Baird decreased their target price on Karyopharm Therapeutics from $42.00 to $25.00 and set an "outperform" rating for the company in a research note on Tuesday, August 12th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Karyopharm Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $34.00.
Check Out Our Latest Report on KPTI
Karyopharm Therapeutics Stock Performance
Karyopharm Therapeutics stock opened at $5.90 on Wednesday. The firm has a market cap of $51.15 million, a price-to-earnings ratio of -0.40 and a beta of 0.34. Karyopharm Therapeutics has a 52-week low of $3.51 and a 52-week high of $16.95. The firm has a 50 day moving average price of $5.93 and a two-hundred day moving average price of $5.16.
Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($4.32) EPS for the quarter, missing analysts' consensus estimates of ($3.80) by ($0.52). The firm had revenue of $37.93 million for the quarter, compared to the consensus estimate of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. Baird Financial Group Inc. acquired a new stake in Karyopharm Therapeutics in the second quarter valued at approximately $45,000. XTX Topco Ltd acquired a new position in shares of Karyopharm Therapeutics during the second quarter worth approximately $56,000. Two Sigma Investments LP lifted its holdings in shares of Karyopharm Therapeutics by 60.3% in the 4th quarter. Two Sigma Investments LP now owns 137,786 shares of the company's stock worth $93,000 after purchasing an additional 51,856 shares in the last quarter. Bridgeway Capital Management LLC acquired a new stake in Karyopharm Therapeutics in the 2nd quarter valued at $163,000. Finally, Silverback Asset Management LLC increased its stake in Karyopharm Therapeutics by 40.0% during the 2nd quarter. Silverback Asset Management LLC now owns 70,000 shares of the company's stock valued at $302,000 after purchasing an additional 20,000 shares in the last quarter. 66.44% of the stock is owned by institutional investors and hedge funds.
About Karyopharm Therapeutics
(
Get Free Report)
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Karyopharm Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Karyopharm Therapeutics wasn't on the list.
While Karyopharm Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
